We are investigating Rybelsus lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk.
The best Rybelsus lawsuits would be for people who were diagnosed with hemorrhagic pancreatitis or necrotizing pancreatitis before October 2025. This is because in October 2025 warnings about pancreatitis were added to the Rybelsus “drug label”. Insofar as there were no Rybelsus pancreatitis warnings until October 2025, there is a possible “failure to warn” products liability claim for people who were diagnosed with pancreatitis before October 2025.
Pancreatitis death cases involving hemorrhagic pancreatitis or necrotizing pancreatitis death would be the most significant Rybelsus lawsuits in terms of legal compensation and liability compared to cases where the pancreatitis went away after a person stopped using Rybelsus.
We point out that Rybelsus pancreatitis cases that were diagnosed after October 2025 are less likely to be filed as Rybelsus lawsuits due to the October 2025 drug label change that added this new warning:
5.2 Acute Pancreatitis
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide tablets [see Adverse Reactions (6)]. After initiation of RYBELSUS or OZEMPIC tablets, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue RYBELSUS or OZEMPIC tablets and initiate appropriate management.
Drug injury attorney Tom Lamb is reviewing possible Rybelsus lawsuits for pancreatitis death cases. You can submit an online Case Evaluation Form, email him (TJL@LambLawOffice.com), or call him (910-256-2971). This case review is free, confidential, and there is no obligation.
[Read the article in full at Drug Injury Watch]Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation